These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 35958603

  • 1. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
    Zhang X, Yang R, Wu T, Cai X, Li G, Yu K, Li Y, Ding R, Dong C, Li J, Hu R, Feng Q, Li Y.
    Front Immunol; 2022; 13():913483. PubMed ID: 35958603
    [Abstract] [Full Text] [Related]

  • 2. Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study.
    Yang R, Wu T, Yu J, Cai X, Li G, Li X, Huang W, Zhang Y, Wang Y, Yang X, Ren Y, Hu R, Feng Q, Ding P, Zhang X, Li Y.
    Front Immunol; 2023; 14():1182299. PubMed ID: 37441082
    [Abstract] [Full Text] [Related]

  • 3. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
    Pei F, Wu J, Zhao Y, He W, Yao Q, Huang M, Huang J.
    Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
    [Abstract] [Full Text] [Related]

  • 4. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ, Xiong Z, Xiao BY, Yu GY, Li YJ, Yao YF, Tao KX, Ding PR, Zhang W, Wu AW.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar 25; 25(3):219-227. PubMed ID: 35340171
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
    Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y, Ding R, Yang R, Tan J, Zhang L, Zhang Y, Wang Y, Dong C, Li Y.
    Front Immunol; 2022 Mar 25; 13():795972. PubMed ID: 35371084
    [Abstract] [Full Text] [Related]

  • 6. [Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction].
    Li YJ, Yuan P, Zhai JN, Yao YF, Tan LX, Li ZW, Zhang XY, Wu AW.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul 25; 27(7):684-693. PubMed ID: 39004983
    [Abstract] [Full Text] [Related]

  • 7. Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR/MSI-H locally advanced colorectal cancer.
    Deng Z, Luo Y, Chen X, Pan T, Rui Y, Hu H, Yan J, Zhang K, Luo C, Song B.
    Front Immunol; 2024 Jul 25; 15():1466497. PubMed ID: 39399495
    [Abstract] [Full Text] [Related]

  • 8. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J, Stintzing S, Haase O, Koch C, Ziegler P, Demes M, Jelas I.
    Oncologist; 2021 Dec 25; 26(12):e2110-e2114. PubMed ID: 34431576
    [Abstract] [Full Text] [Related]

  • 9. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
    Wang YQ, Shen LJ, Wan JF, Zhang H, Wang Y, Wu X, Wang JW, Wang RJ, Sun YQ, Tong T, Huang D, Wang L, Sheng WQ, Zhang X, Cai GX, Xu Y, Cai SJ, Zhang Z, Xia F.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May 25; 26(5):448-458. PubMed ID: 37217353
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, Lan P, Wu X, Wang C, Cao W, Hu J, Huang Y, Huang L, Wang H, Shi L, Cai Y, Shen C, Ling J, Xie X, Cai Y, He X, Dou R, Zhou J, Ma T, Zhang X, Luo S, Deng W, Ling L, Liu H, Deng Y.
    Lancet Gastroenterol Hepatol; 2022 Jan 25; 7(1):38-48. PubMed ID: 34688374
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer.
    Li Y, Zhang W, Du J, Hu J, Hu R, Zeng Z, Jin-Si-Han EE, Lian S, Wang H, Li Y, Pan Z, Feng C, Zhang X, Lu Z.
    Target Oncol; 2024 Jul 25; 19(4):601-610. PubMed ID: 38691294
    [Abstract] [Full Text] [Related]

  • 12. Pathological complete response after neoadjuvant immunotherapy combined with chemotherapy in pediatric rectal carcinoma: A case report.
    Cao X, Luo J, Zhao B, Fu H, Kang W.
    Front Immunol; 2022 Jul 25; 13():1036181. PubMed ID: 36544760
    [Abstract] [Full Text] [Related]

  • 13. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ, Zhang L, Dong QS, Cai Y, Zhang YZ, Wang L, Yao YF, Zhang XY, Li ZW, Li YH, Sun YS, Wang WH, Wu AW.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov 25; 24(11):998-1007. PubMed ID: 34823301
    [Abstract] [Full Text] [Related]

  • 14. Pathological Complete Response Following Neoadjuvant Tislelizumab Monotherapy in Treatment-Naive Locally Advanced, MMR-Deficient/MSI-High Ascending Colon Cancer: A Case Report.
    Hei Y, Yang R, Kong S, Zhang H, Chen Y.
    J Clin Med; 2022 Dec 28; 12(1):. PubMed ID: 36615039
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series.
    Pan T, Yang H, Wang WY, Rui YY, Deng ZJ, Chen YC, Liu C, Hu H.
    Clin Colorectal Cancer; 2024 Mar 28; 23(1):104-110. PubMed ID: 38336555
    [Abstract] [Full Text] [Related]

  • 16. Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series.
    Zhou C, Jiang T, Xiao Y, Wang Q, Zeng Z, Cai P, Zhao Y, Zhao Z, Wu D, Lin H, Sun C, Zhang R, Xiao W, Gao Y.
    Front Immunol; 2021 Mar 28; 12():784336. PubMed ID: 34975873
    [Abstract] [Full Text] [Related]

  • 17. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
    Yu JH, Xiao BY, Li DD, Jiang W, Ding Y, Wu XJ, Zhang RX, Lin JZ, Wang W, Han K, Kong LH, Zhang XK, Chen BY, Mei WJ, Pan ZZ, Tang JH, Zhang XS, Ding PR.
    Lancet Oncol; 2024 Jul 28; 25(7):843-852. PubMed ID: 38852601
    [Abstract] [Full Text] [Related]

  • 18. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.
    Xiao BY, Zhang X, Cao TY, Li DD, Jiang W, Kong LH, Tang JH, Han K, Zhang CZ, Mei WJ, Xiao J, Pan ZZ, Li YF, Zhang XS, Ding PR.
    J Natl Compr Canc Netw; 2023 Jan 28; 21(1):60-66.e5. PubMed ID: 36630898
    [Abstract] [Full Text] [Related]

  • 19. Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti-PD-1-Based Immunotherapy as Curative-Intent Treatment.
    Yu JH, Liao LE, Xiao BY, Zhang X, Wu AW, Cheng Y, Tang JH, Jiang W, Kong LH, Han K, Mei WJ, Hong ZG, Yang WJ, Li DD, Pan ZZ, Li YF, Zhang XS, Ding PR.
    J Natl Compr Canc Netw; 2024 Mar 18; 22(3):. PubMed ID: 38498975
    [Abstract] [Full Text] [Related]

  • 20. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
    Zhou L, Yang XQ, Zhao GY, Wang FJ, Liu X.
    Front Immunol; 2023 Mar 18; 14():1044353. PubMed ID: 36776899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.